BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology Therapeutics, Inc. (BBOT): 19 pipeline candidates · 3 upcoming catalysts · ~21 mo cash runway · 12 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
20.6 months
D/E 0.12 · 0% dilution
Lead: Phase 2
19 candidates
3 upcoming, next in ~193d
N/A
A transparent, data-derived signal for BridgeBio Oncology Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$614.4M
Cash
$52.8M
Quarterly Burn
$35.9M
Runway
20.6 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (19 candidates)
| Drug | Phase |
|---|---|
| BBO-10203 | Phase 1 |
| bbo-11818 | Phase 1 |
| BBO-8520 | Phase 1 |
| Binimetinib | Phase 2 |
| cetuximab | Phase 1 |
| Emavusertib | Phase 1 |
| Floxuridine | Phase 2 |
| FOLFIRI | Phase 1 |
| FOLFOX | Phase 1 |
| Givastomig | Phase 2 |
Showing 10 of 19 candidates. Sign up for full pipeline.
Upcoming Catalysts (3)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
64
Total value held
$305.2M
| Holder | Shares | Value |
|---|---|---|
| deerfield management company, l.p. | 4,885,446 | $43.7M |
| omega fund management, llc | 3,289,661 | $29.4M |
| wellington management group llp | 2,818,348 | $25.2M |
| enavate sciences gp, llc | 2,626,946 | $23.5M |
| citadel advisors llc | 2,528,762 | $22.6M |
| novo holdings a/s | 2,185,923 | $19.6M |
| blackrock, inc. | 2,088,297 | $18.7M |
| laurion capital management lp | 1,922,656 | $17.2M |
| armistice capital, llc | 1,328,000 | $11.9M |
| vanguard capital management llc | 1,076,882 | $9.6M |
Showing top 10 of 64 institutional holders of BridgeBio Oncology Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in BridgeBio Oncology Therapeutics, Inc.'s pipeline?
BridgeBio Oncology Therapeutics, Inc. (BBOT) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is BridgeBio Oncology Therapeutics, Inc.'s lead drug candidate?
BridgeBio Oncology Therapeutics, Inc.'s most advanced tracked candidate is BBO-10203 (Phase 1) for Non-small Cell Lung Cancer; Non-Small Cell Lung Cancer; Solid Tumor, Adult.
What is BridgeBio Oncology Therapeutics, Inc.'s next catalyst?
BridgeBio Oncology Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: Early Commencement of Adjuvant Chemotherapy for Stage III Colon Cancer: a Multicenter Randomized Tri" — expected December 28, 2026.
What is BridgeBio Oncology Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, BridgeBio Oncology Therapeutics, Inc. has approximately 20.6 months of cash runway.
What is BridgeBio Oncology Therapeutics, Inc.'s market capitalization?
BridgeBio Oncology Therapeutics, Inc.'s market capitalization is approximately $614.4M.
Get the full picture on BridgeBio Oncology Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.